hematopoiet
stem
cell
transplant
hsct
treatment
hematolog
malign
immun
defici
genet
diseas
ect
recent
number
hsct
perform
korea
increas
outcom
improv
howev
infecti
complic
account
morbid
mortal
hsct
posthsct
infecti
complic
usual
classifi
accord
time
hsct
preengraft
immedi
postengraft
late
postengraft
period
addit
type
risk
factor
infecti
complic
differ
accord
stem
cell
sourc
donor
type
condit
intens
region
prophylaxi
strategi
comorbid
graftversushost
diseas
invas
fungal
infect
review
summar
infecti
complic
hsct
focus
korean
perspect
hematopoiet
stem
cell
transplant
hsct
known
previous
bone
marrow
transplant
perform
treat
two
broad
categori
diseas
first
categori
consist
function
failur
bone
marrow
marrowderiv
cell
includ
aplast
anemia
myelodysplast
syndrom
immunodefici
syndrom
sever
combin
immun
defici
chronic
granulomat
diseas
genet
diseas
mucopolysaccharidosi
glycogen
storag
diseas
etc
hemoglobinopathi
thalassemia
sickl
cell
anemia
etc
case
hsct
appli
replac
defect
nonfunct
bone
marrow
tissu
diseas
second
categorywhich
includ
hematolog
malign
acut
chronic
leukemia
multipl
myeloma
lymphoma
myeloprolif
neoplasmsar
common
indic
hsct
perform
aim
restor
myelosuppress
myeloabl
effect
cytotox
treatment
intens
chemotherapi
andor
total
bodi
irradi
tbi
elimin
malign
cell
induc
graftversusleukem
effect
provid
antineoplast
immun
cell
express
tumorspecif
associ
antigen
hsct
simpli
classifi
au
tolog
allogen
accord
donor
statu
surviv
rate
low
sinc
introduct
human
leukocyt
antigen
hla
concept
incid
graft
failur
andor
graftversushost
diseas
gvhd
decreas
recent
year
allogen
hsct
involv
variou
sourc
hematopoiet
stem
cell
bone
marrow
peripher
stem
cell
cord
blood
mesenchym
cell
donor
sibl
unrel
haploident
condit
regimen
standard
myeloabl
reduc
intens
support
therapi
transfus
coloni
stimul
factor
antimicrobi
agent
also
develop
although
variou
earli
diagnosi
therapeut
techniqu
develop
improv
transplant
perform
infecti
diseas
still
affect
prognosi
hsct
recipi
korea
hsct
first
perform
number
transplant
rapidli
increas
past
year
addit
suscept
infecti
diseas
due
neutropenia
immedi
hsct
delay
immun
recoveri
evid
long
period
time
engraft
depend
type
hsct
immunosuppress
acut
chronic
gvhd
preval
infecti
diseas
vari
geograph
time
stateoftheart
knowledg
need
manuscript
infecti
complic
hsct
particularli
common
korea
review
well
epidemiolog
diagnosi
prevent
therapeut
strategi
novel
drug
improv
outcom
patient
posthsct
period
usual
divid
preengraft
period
day
day
immedi
postengraft
period
engraft
day
late
postengraft
period
day
gener
neutrophil
count
recov
week
hsct
howev
function
recoveri
variou
cell
type
also
import
immunolog
recoveri
take
month
nk
cell
month
bcell
tcell
year
tcell
use
tcelldeplet
agent
antithymocyt
globulin
atg
alemtuzumab
etc
reduc
risk
gvhd
graft
failur
could
improv
outcom
transplant
may
delay
immun
recoveri
recipi
tcelldeplet
transplant
may
vulner
viral
infectionssuch
cytomegaloviru
cmv
epsteinbarr
viru
ebv
adenovirusand
adopt
immunotherapi
may
appli
preengraft
period
risk
opportunist
infect
vari
depend
type
anticanc
drug
use
condit
intens
myeloabl
reduc
intens
presenc
acut
gvhd
autolog
hsct
lead
rapid
recoveri
immun
function
allogen
hsct
postengraft
period
immun
system
reconstitut
recov
autolog
hsct
recipi
howev
allogen
hsct
recipi
undergo
longterm
immunosuppress
therapi
chronic
gvhd
remain
risk
infect
tabl
show
risk
factor
infecti
diseas
commonli
encount
hsct
shown
tabl
infecti
diseas
occur
engraft
similar
develop
neutropen
phase
chemotherapi
neutrophil
import
innat
immun
microorgan
decreas
number
neutrophil
increas
suscept
infect
addit
patient
neutropenia
reduc
number
leukocyt
therefor
inflammatori
find
common
patient
normal
leukocyt
count
often
seen
except
fever
difficult
diagnos
appropri
time
start
treatment
may
miss
main
sourc
bacteri
infect
preengraft
phase
normal
gastrointestin
flora
indwel
vascular
cathet
gramneg
bacilli
gnb
common
pathogen
former
gramposit
cocci
gpc
common
latter
gener
microbiolog
defin
infect
mdi
account
case
neutropen
fever
distribut
caus
organ
febril
neutropen
patient
vari
geograph
unit
state
europ
gpc
account
mdi
earli
proport
korean
journal
intern
medicin
vol
march
gnb
increas
multicent
epidemiolog
survey
proport
gramposit
neg
case
rang
rang
respect
enterobacteriacea
common
caus
organ
account
rang
second
common
organ
coagulaseneg
staphylococci
rang
korean
studi
gnb
also
common
consist
report
asiapacif
region
intestin
bacteria
escherichia
coli
klebsiella
pneumonia
pseudomona
aeruginosa
frequent
report
gnb
enterococcu
streptococcu
staphylococcu
speci
common
among
gpc
epidemiolog
bacteri
pathogen
resist
profil
vari
earli
empir
antimicrobi
agent
must
select
accord
distribut
suscept
frequent
detect
bacteri
taxa
center
late
postengraft
phase
autolog
hsct
immun
system
reconstitut
restor
consist
time
chronic
gvhd
typic
develop
allogen
hsct
therefor
autolog
transplant
recipi
rare
experi
opportunist
infect
time
allogen
hsct
recipi
take
chronic
immunosuppress
drug
sever
month
risk
infect
period
infecti
diseas
may
continu
develop
addit
immun
defici
result
chronic
gvhd
associ
infect
encapsul
bacteria
streptococcu
pneumonia
haemophilu
influenza
neisseria
meningitidi
defici
immunoglobulin
report
patient
chronic
sever
gvhd
associ
sever
pneumonia
mening
sepsi
due
pneumonia
earli
diagnosi
treatment
essenti
vaccin
emphas
highrisk
group
patient
immun
hsct
describ
separ
section
review
past
decad
frequenc
detect
resist
bacteria
increas
worldwid
includ
patient
neutropen
fever
hematolog
malign
among
extendedspectrum
esbl
produc
enterobacteriacea
k
pneumonia
compris
around
twothird
e
coli
onethird
rang
depend
region
late
e
coli
k
pneumonia
bacteremia
isol
neutropen
patient
esblproduc
strain
singlecent
studi
incid
infect
caus
carbapenemresist
enterobacteriacea
cre
along
esblproduc
enterobacteriacea
increas
hematolog
malign
patient
k
pneumonia
e
coli
p
aeruginosa
acinetobact
baumannii
clinic
import
strain
associ
acquisit
carbapenem
resist
studi
prior
colon
cre
risk
factor
cre
bloodstream
infect
found
neutropen
patient
carbapenemresist
k
pneumonia
rectal
colon
experienc
bloodstream
infect
ident
strain
multicent
studi
cre
hsct
recipi
howev
singlecent
retrospect
cohort
studi
perform
korea
report
incid
carbapenemresist
baumannii
bacteremia
case
per
patientday
postengraft
infect
organ
fatal
rate
methicillinresist
coagulaseneg
staphylococci
reportedli
higher
center
incid
rate
staphylococcu
aureu
hsct
patient
low
high
methicillinresist
rate
median
rang
late
coagulaseneg
staphylococci
report
methicillin
resist
rate
aureu
rate
incid
enterococcu
bloodstream
infect
case
per
patientday
vancomycinresist
enterococcu
vre
account
vre
bloodstream
infect
caus
e
faecium
associ
longterm
hospit
underli
medic
condit
resist
associ
mortal
epidemiolog
drugresist
pathogen
import
establish
strategi
prophylaxi
initi
empir
antimicrobi
therapi
domest
data
limit
singleinstitut
retrospect
studi
multicent
nationwid
studi
epidemiolog
bacteri
infect
korea
requir
prophylaxi
play
import
role
preengraft
phase
tabl
oral
fluoroquinolon
prophylaxi
reduc
febril
neutropen
episod
relat
mortal
allogen
hsct
recipi
accord
guidelin
infecti
diseas
societi
america
infecti
diseas
work
parti
german
societi
hematolog
oncolog
ciprofloxacin
levofloxacin
equal
effect
levofloxacin
may
effect
term
broader
coverag
viridan
streptococci
oral
mucos
present
although
fluoroquinolon
prophylaxi
led
increas
frequenc
drugresist
includ
quinolon
pathogen
benefit
reportedli
outweigh
risk
fluoroquinolon
prophylaxi
decreas
rate
identif
p
aeruginosa
howev
fluoroquinolon
prophylaxi
reportedli
correl
resist
develop
clostridium
difficileassoci
diarrhea
moreov
fluoroquinolon
prophylaxi
may
reduc
rate
bloodstream
infect
overal
mortal
rate
therefor
benefit
routin
fluoroquinolon
prophylaxi
weigh
toxic
effect
local
epidemiolog
neutropen
patient
preengraft
phase
infect
progress
rapidli
addit
difficult
distinguish
bacteri
infect
noninfecti
fever
earli
stage
empir
antimicrobi
therapi
recommend
immedi
patient
febril
neutropen
episod
except
presenc
definit
infect
foci
broadspectrum
antibiot
ceftazidim
cefepim
piperacillintazobactam
carbapenem
recommend
activ
gramposit
neg
bacteria
includ
p
aeruginosa
stepdown
therapi
consid
initi
regimen
compris
two
antimicrobi
agent
depend
local
epidemiolog
resist
profil
deescal
approach
gener
recommend
high
incid
resist
pathogen
neu
korean
journal
intern
medicin
vol
march
tropen
fever
high
colon
rate
multipl
drug
resist
bacteria
patient
histori
infect
drugresist
pathogen
howev
data
cutoff
resist
insuffici
formul
strategi
addit
random
control
studi
compar
therapeut
efficaci
escal
deescal
approach
hsct
recipi
select
appropri
strategi
take
account
patient
condit
preval
resist
organ
center
aspergillu
speci
common
caus
invas
fungal
infect
ifi
patient
hematolog
diseas
follow
candida
spp
rare
fungi
caus
fungi
differ
hsct
characterist
risk
factor
fungal
infect
differ
accord
phase
transplant
preengraft
period
neutropenia
mucos
damag
risk
factor
invas
candidiasi
antifung
prophylaxi
regimen
use
andor
hsct
list
tabl
recent
advanc
use
prophylact
antifung
agent
hsct
led
chang
epidemiolog
candidiasi
korean
epidemiolog
data
show
incid
candida
albican
infect
markedli
reduc
antifung
prophylaxi
nonetheless
incid
c
albican
decreas
increas
prophylact
use
fluconazol
echinocandin
attent
paid
select
antifung
agent
empir
target
therapi
invas
candidiasi
postengraft
risk
candida
infect
decreas
recoveri
neutropenia
mucos
skin
loss
risk
aspergillosi
remain
invas
aspergillosi
ia
develop
neutropen
period
typic
involv
angioinvas
due
host
immunosuppress
contrast
ia
occur
nonneutropen
patient
usual
due
longterm
use
steroid
immunosuppress
agent
gvhd
like
caus
local
inflamm
ie
airway
invas
vascular
invas
seifem
studi
frequent
etiolog
agent
ifi
aspergillu
candida
speci
ifiattribut
mortal
rate
allogen
hsct
recipi
autolog
hsct
recipi
prospect
observ
studi
perform
asiapacif
region
tabl
exampl
therapi
antimicrobi
prophylaxi
intermedi
autologu
hsct
anticip
neutropenia
less
day
bacteria
consid
fluoroquinolon
prophylaxi
neutropenia
fungu
consid
prophylaxi
neutropenia
anticip
mucos
consid
pcp
prophylaxi
viru
neutropenia
longer
depend
risk
high
allogenen
hsct
includ
unrel
famili
mismatch
donor
anticip
neutropenia
day
prolong
neutropenia
secondari
neutropenia
engraft
statu
malign
remiss
ghvd
signific
steroid
treatment
mgday
prednisolon
equival
use
secondari
immunosuppress
agent
due
refractori
gvhd
eg
inhibitor
bacteria
consid
fluoroquinolon
fungu
consid
prophylaxi
neutropenia
consid
pcp
prophylaxi
viru
neutropenia
longer
depend
risk
hsct
hematopoiet
stem
cell
transplant
pcp
pneumocysti
jirovecii
pneumonia
gvhd
graftversushost
diseas
tumor
necrosi
recent
data
concern
correl
fluoroquinolon
prophylaxi
develop
resist
clostridium
difficil
associ
diarrhea
ia
account
ifi
follow
invas
candidiasi
interestingli
aspergillu
spp
major
fungal
pathogen
center
thailand
vietnam
probabl
galactomannan
test
unavail
heterogen
diagnost
prophylact
therapeut
approach
ifi
necessit
local
epidemiolog
data
incid
ifi
higher
allogen
autolog
hsct
establish
risk
factor
includ
chronic
gvhd
steroid
use
accord
recent
multicent
studi
perform
korea
risk
studi
cumul
incid
ifi
transplant
therefor
activ
antimold
prophylaxi
consid
patient
risk
factor
current
voriconazol
avail
korea
secondari
prophylaxi
ia
hsct
posaconazol
patient
signific
immunosuppress
agent
gvhd
diagnosi
ifi
hsct
markedli
differ
engraft
howev
comput
tomographi
ct
find
invas
pulmonari
aspergillosi
patient
hematolog
diseas
may
differ
depend
time
neutropenia
time
neutrophil
recoveri
hsct
suggest
diagnost
criteria
may
need
redefin
diagnos
ifi
radiolog
examin
chest
xray
ct
microbiolog
studi
includ
fungal
cultur
galactomannan
assay
perform
period
accur
diagnosi
bronchoscopi
bronchoalveolar
lavag
bal
fluid
examin
lung
biopsi
cultur
requir
voriconazol
drug
choic
treat
ia
voriconazol
therapeut
drug
monitor
use
mani
center
target
trough
level
mgl
polymorph
affect
pharmacokinet
voriconazol
among
korean
hematolog
patient
extens
metabol
em
heterozyg
em
poor
metabol
subtherapeut
initi
trough
level
common
em
signific
relationship
genotyp
clinic
outcom
ia
toxic
voriconazol
isavuconazol
noninferior
voriconazol
primari
treatment
suspect
invas
mold
diseas
fewer
drugrel
advers
event
salvag
therapi
includ
liposom
amphotericin
b
caspofungin
posaconazol
itraconazol
combin
treatment
durat
least
week
individu
accord
chang
radiolog
microbiolog
immunolog
paramet
ifi
occur
treatment
antimold
agent
patient
gvhd
longterm
immunosuppress
therapi
antifung
agent
prevent
ifi
tabl
particular
risk
ifi
aspergillosi
mucormycosi
rare
mold
retrospect
singlecent
studi
report
preval
incid
voriconazolebreakthrough
ifi
case
per
year
respect
overal
mortal
rate
possibl
caus
breakthrough
ifi
voriconazol
treatment
persist
immunodefici
neutropenia
low
voriconazol
concentr
poor
vascular
suppli
ie
abscess
necrot
tissu
voriconazolerefractori
ia
clinician
consid
follow
misdiagnosi
coinfect
anoth
mold
inadequ
blood
voriconazol
concentr
inadequ
tissu
drug
concentr
immun
reconstitut
inflammatori
syndrom
infect
voriconazoleresist
aspergillu
provenprob
ia
patient
reportedli
low
cultureposit
rate
determin
azoleresist
rate
aspergillu
clinic
isol
korea
cultureposit
case
undergo
suscept
test
major
symptom
pneumocysti
jirovecii
pneumonia
pcp
fever
difficulti
breath
dri
cough
rather
purul
sputum
typic
radiolog
find
bilater
diffus
infiltr
origin
peripheri
lung
may
normal
begin
pcp
present
segment
consolid
upper
lobe
subtl
ground
glass
opac
pneumothorax
usual
occur
within
month
transplant
also
month
immunosuppress
therapi
chronic
gvhd
known
risk
factor
pcp
hematolog
patient
acut
lymphoblast
leukemia
allogen
hsct
recipi
alemtuzumab
fludarabin
cyclophosphamid
rituximab
steroid
use
mgday
prednison
week
pcp
clinic
suspect
ct
bronchoscopi
bal
perform
earli
possibl
retrospect
studi
bronchial
wash
bal
fluid
nonhuman
immunodefici
viru
hiv
infect
patient
suspect
respiratori
infect
among
polymeras
chain
reaction
pcr
posit
patient
classifi
pcp
nonpcp
major
patient
nonpcp
group
recov
without
treatment
pcp
two
recent
metaanalys
sensit
specif
quantit
pcr
qpcr
assay
superior
nonqpcr
assay
serum
test
result
high
negativepredict
valu
use
followup
pcp
prognosi
wors
presenc
concomit
infecti
diseas
particularli
cmv
aspergillu
steroid
use
adjunct
therapi
patient
hypoxia
pao
mmhg
pao
pao
mmhg
incid
pcp
significantli
reduc
trimethoprimsulfamethoxazol
prophylaxi
highrisk
patient
highrisk
patient
take
prophylaxi
show
poor
complianc
drug
regimen
main
popul
risk
pcp
systemat
review
metaanalysi
nonhiv
immunocompromis
host
patient
acut
leukemia
recipi
hsct
solid
organ
transplant
incid
pcp
reduc
rel
risk
rr
trimethoprimsulfamethoxazol
prophylaxi
group
compar
placebo
addit
pcprelat
mortal
significantli
reduc
rr
howev
trimethoprimsulfamethoxazol
prophylaxi
markedli
reduc
allcaus
mortal
hematolog
popul
mortal
rate
remain
high
hematolog
patient
particularli
hsct
recipi
compar
patient
hiv
infect
nevertheless
given
sever
cours
pcp
higher
pcprelat
mortal
rate
trimethoprimsulfamethoxazol
prophylaxi
like
save
live
wwwkjimorg
http
immunocompromis
group
well
pcp
prevent
least
month
immunosuppress
discontinu
allogen
hsct
recipi
although
optimum
durat
pcp
prophylaxi
controversi
suggest
continu
period
time
immunosuppress
discontinu
set
corticosteroidcontain
regimen
prophylaxi
continu
steroid
wean
andor
week
cessat
chemotherapi
regimen
ie
alemtuzumab
consider
given
extend
pcp
prophylaxi
month
high
rate
lateonset
pcp
tabl
summar
method
prevent
pcp
hsct
cmv
infect
occur
hsct
fatal
cmv
reactiv
patient
reinfect
transplant
spectrum
cmv
infect
extens
cmv
reactiv
without
organ
involv
present
mainli
asymptomat
antigenemia
dnaemia
cmv
diseas
esophag
gastriti
coliti
hepat
pneumonia
retin
enceph
addit
direct
organ
involv
cmv
reactiv
exert
indirect
effectssuch
graft
failur
immunosuppressionthat
may
result
develop
concurr
bacteri
andor
fungal
infect
cmv
diseas
especi
cmv
pneumonia
enceph
fatal
despit
aggress
anticmv
therapi
retrospect
singlecent
studi
perform
korea
report
cmv
diseas
occur
allogen
hsct
recipi
autolog
hsct
recipi
pneumonia
retin
enter
frequent
develop
patient
cmv
infect
averag
time
onset
cmv
diseas
day
transplant
rang
day
anoth
studi
institut
report
cmv
dnaemia
develop
hsct
recipi
cmv
reactiv
associ
higher
nonrelaps
mortal
rate
rr
anoth
report
hsct
recipi
experienc
level
cmv
antigenemia
receiv
ganciclovir
therapi
signific
cmv
reactiv
cmv
diseas
howev
incid
could
underestim
diseas
preval
evalu
patient
undergo
preemptiv
therapi
diagnosi
cmv
diseas
base
patholog
find
diagnosi
might
limit
depend
patient
condit
particularli
diagnosi
cmv
pneumonia
obtain
lung
tissu
critic
ill
patient
transbronchi
lung
biopsi
problemat
one
studi
aim
measur
cmv
level
bronchial
wash
fluid
suggest
cutoff
pneumonia
diagnosi
cmv
dnaemia
copiesml
iuml
may
associ
cmv
pneumonia
posthsct
patient
determin
receiv
oper
characterist
curv
howev
data
need
difficult
distinguish
whether
viral
dna
alveolar
hemorrhag
reflect
viremia
rather
lung
tissu
involv
whether
cmv
detect
bystand
bronchial
wash
fluid
manag
cmv
categor
prevent
preemptiv
treatment
definit
treatment
preemptiv
therapi
anticmv
treatment
even
absenc
clinic
symptom
case
cmv
infect
reinfect
reactiv
transplant
center
introduc
preemptiv
therapi
rather
routin
univers
prevent
insur
coverag
costbenefit
ratio
advers
drug
reaction
studi
monitor
strategi
earli
detect
result
use
cmv
antigenemia
test
realtim
qpcr
surveil
identif
patient
suitabl
preemptiv
therapi
howev
hsct
relationship
cmv
viral
load
cmv
diseas
differ
solid
organ
transplant
cmv
gastrointestin
diseas
develop
without
preced
cmv
antigenemia
dnaemia
copiesml
cmv
dnaemia
reportedli
associ
increas
risk
cmv
retin
hsct
howev
correl
moder
antigenemia
dnaemia
necessarili
preced
accompani
cmv
diseas
therefor
import
identifi
atrisk
group
clinic
featur
variou
cmv
diseas
facilit
earli
diagnosi
treatment
recent
prospect
doubleblind
trial
evalu
letermovir
prophylaxi
prevent
cmv
hsct
recipi
total
patient
underw
random
receiv
letermovir
placebo
week
transplant
incid
clinic
signific
cmv
infect
lower
letermovir
group
placebo
group
week
transplant
patient
vs
patient
p
letermovir
prophylaxi
result
significantli
lower
risk
clinic
signific
cmv
infect
placebo
advers
event
letermovir
mainli
low
grade
result
us
food
drug
administr
approv
letermovir
prevent
cmv
infect
diseas
adult
cmvseroposit
patient
undergo
allogen
hsct
korea
high
cmvseroposit
rate
adult
donor
recipi
seroposit
dr
frequenc
cmv
infect
transplant
addit
owe
activ
cmv
monitor
preemptiv
therapi
decreas
incid
cmv
infect
immedi
transplant
howev
late
cmv
infect
month
transplant
increas
especi
cmvspecif
tcell
function
restor
due
chronic
gvhd
therefor
immun
monitor
requir
patient
highrisk
cmv
diseas
cmvspecif
immun
recoveri
studi
kidney
transplant
kt
hsct
recipi
cmvspecif
cytotox
lymphocyt
ctl
play
import
role
reconstitut
cmvspecif
immun
immunocompromis
patient
method
use
evalu
cmvspecif
immun
includ
tetram
assay
intracellular
cytokin
analysi
flow
cytometri
measur
secret
cmvspecif
tcell
enzymelink
immunospot
assay
use
peptid
pool
quantif
cmvspecif
tcell
immun
hsct
facilit
identif
patient
risk
cmvrelat
complic
current
avail
anticmv
agent
korea
ganciclovir
valganciclovir
foscarnet
cidofovir
sinc
februari
use
valganciclovir
hsct
patient
cmv
infect
increas
due
chang
reimburs
rule
regard
advers
event
attent
paid
bone
marrow
suppress
patient
renal
insuffici
gvhd
use
wwwkjimorg
http
monoclon
antibodi
ie
alemtuzumab
increas
incid
cmv
infect
infect
may
distinguish
gvhd
may
coexist
gvhd
may
respond
antivir
drug
diagnosi
delay
persist
infect
despit
anticmv
therapi
cmv
refractori
consid
log
decreas
cmv
dna
level
blood
plasma
achiev
week
treatment
cmvrefractori
case
resist
also
suspect
although
cmv
resist
remain
uncommon
hsct
recipi
hlamatch
donor
highrisk
patient
incid
cmv
resist
gold
standard
cmv
resist
test
increas
ic
half
maxim
inhibitori
concentr
valu
plaqu
reduct
assay
howev
cmv
resist
defin
one
genet
mutat
associ
ganciclovir
valganciclovir
foscarnet
cidofocir
identifi
clinic
refractori
therefor
recent
year
mutat
test
predispos
factor
cmv
resist
includ
prolong
use
anticmv
agent
recurr
cmv
infect
inadequ
antivir
absorpt
subtherapeut
antivir
level
haploident
transplant
tcell
deplet
resist
confirm
drug
resist
identifi
combin
drug
may
use
treatment
current
limit
clinician
experi
import
complic
case
herp
zoster
caus
reactiv
viru
latent
posterior
ganglia
primari
infect
varicella
zoster
viru
vzv
korea
vzv
transmit
natur
infect
case
seropreval
adult
previou
vzv
infect
prerequisit
herp
zoster
clinic
featur
herp
zoster
includ
abnorm
sensat
pain
skin
segment
day
skin
lesion
develop
erythemat
spot
irrit
rapid
format
blister
blister
burst
form
ulcer
scar
becom
dri
pain
postherpet
neuralgia
major
problem
case
one
two
dermatom
involv
unilater
dissemin
sever
dermatom
system
occur
associ
viscer
central
nervou
system
involv
treatment
consist
antivir
administr
adjuv
therapi
reduc
acut
pain
postherpet
neuralgia
clear
whether
antivir
treatment
effect
hour
onset
rash
howev
immunocompromis
patient
persist
new
vesicular
rash
eye
involv
andor
neurolog
complic
receiv
antivir
treatment
even
hour
onset
risk
varicella
highest
first
month
hcst
immunosuppress
therapi
gvhd
korean
transplant
center
patient
underw
allogen
hsct
experienc
herp
zoster
cumul
incid
year
posttranspl
year
fig
chest
dermatom
commonli
involv
case
dissemin
herpeszosterrel
mortal
live
attenu
zoster
vaccin
avail
use
hsct
recipi
acyclovir
prophylaxi
reduc
incid
herp
simplex
viru
hsv
vzv
infect
engraft
also
long
term
immunosuppress
stop
recommend
acyclovir
maintain
least
year
allogen
hsct
month
autolog
hsct
antivir
prophi
ebv
reactiv
occur
month
transplant
typic
patient
chronic
gvhd
howev
progress
diseas
rel
rare
fever
neutropenia
may
occur
result
ebv
symptom
similar
infecti
mononucleosi
ebv
reactiv
subclin
requir
therapi
addit
aplast
anemia
oral
hairi
leukoplakia
posttranspl
lymphoprolif
diseas
ptld
occur
ptld
occur
less
frequent
hsct
transplant
solid
organ
ebvrel
ptld
occur
case
unrel
donor
transplant
tcelldeplet
transplant
gvhd
use
antilymphocyt
antibodi
prevent
gvhd
diagnosi
ebvassoci
ptld
establish
tissu
biopsi
histopatholog
detect
ebv
among
herpesvirus
human
herp
viru
may
respons
mening
hemorrhag
cystiti
hemorrhag
cystiti
hsct
recipi
classifi
accord
onset
time
vs
engraft
case
occur
within
day
transplant
usual
noninfecti
noninfecti
caus
includ
radiotherapi
chemotherapi
eg
cyclophosphamid
ifosfamid
busulfan
etoposid
postengraft
hemorrhag
cystiti
caus
viru
viral
reactiv
accompani
bladder
urotheli
damag
due
condit
regimen
viral
hemorrhag
cystiti
caus
polyomavirus
bk
jc
virus
adenoviru
cmv
hsv
virus
bk
viru
bkv
common
adult
bkv
seroposit
bkvassoci
hemorrhag
cystiti
predomin
allogen
hsct
patient
bkvassoci
nephropathi
kt
patient
bkv
reactiv
manifest
two
major
form
kt
hsct
patient
unclear
diagnost
criteria
defin
european
confer
infect
leukemia
ecil
compris
follow
triad
viral
replic
urin
bkv
copiesml
symptom
cystiti
hematuria
grade
ii
higher
blood
bkv
dna
level
copiesml
reportedli
associ
signific
viruria
howev
neg
plasma
viral
load
rule
bkvassoci
hemorrhag
cystiti
risk
factor
hemorrhag
cystiti
myeloabl
condit
regimen
atg
gvhd
incid
higher
allogen
autolog
hsct
patient
adult
pediatr
case
treatment
virusassoci
hemorrhag
cystiti
initi
minim
immunosuppress
cidofovir
might
effect
adenoviru
cmv
bkv
consid
grade
iii
hematuria
gross
hematuria
blood
clot
respons
conserv
treatment
eight
retrospect
two
prospect
studi
use
cidofovir
without
probenecid
either
mgkg
probenecid
mgkg
without
probenecid
investig
reduct
urin
blood
bkv
load
reportedli
occur
patient
respect
retrospect
studi
recommend
levofloxacin
insuffici
data
low
level
evid
addit
retrospect
data
avail
vidarabin
leflunomid
hyaluron
acid
mesenchym
cell
recommend
guidelin
brincidofovir
markedli
reduc
bkv
replic
vitro
case
persist
hematuria
renal
function
impair
blood
clot
relat
postren
obstruct
conserv
care
intraven
hydrat
remov
obstruct
also
import
tient
crv
infect
also
occur
neutropenia
show
signific
morbid
mortal
epidemiolog
crv
infect
hsct
patient
like
reflect
commun
season
variat
influenza
respiratori
syncyti
viru
rsv
infect
usual
occur
winter
parainfluenza
viru
piv
infect
summer
rhinoviru
throughout
year
hsct
recipi
crv
infect
limit
urti
like
progress
lrti
respiratori
viru
multiplex
pcr
enabl
rapid
diagnosi
crv
infect
clinic
practic
littl
data
crv
infect
hsct
patient
korea
retrospect
studi
author
hsct
center
hsct
patient
case
crvlrti
rsv
common
pathogen
crvlrti
follow
piv
influenza
viru
rhinoviru
overal
mortal
rate
day
crvlrti
highdos
steroid
usag
mgkgday
sever
immunodefici
lymphopenia
absolut
lymphocyt
count
cellsmm
significantli
associ
mortal
find
similar
preval
mortal
rate
mortalityrel
risk
factor
crvlrti
europ
unit
state
averag
mortal
rate
rsvlrti
rang
intern
studi
major
risk
factor
progress
lrti
lymphopenia
old
age
mismatchedunrel
donor
neutropenia
case
pivlrti
overal
mortal
rate
highlevel
corticosteroid
exposur
neutropenia
lymphopenia
earli
onset
hsct
major
risk
factor
lrti
rate
progress
influenza
lrti
overal
mortal
rate
risk
factor
progress
influenzalrti
earli
onset
hsct
lymphopenia
old
age
neutropenia
delay
antivir
administr
case
rhinoviru
infect
asymptomat
less
patient
progress
definit
pneumonia
mortal
rate
addit
human
metapneumoviru
adenoviru
coronaviru
bocaviru
caus
urti
lrti
hsct
patient
manag
crv
infect
hsct
patient
classifi
four
categori
prevent
infect
control
select
therapi
urti
antivir
therapi
support
care
current
commerci
vaccin
avail
influenza
prevent
strategi
stop
spread
crv
infectionssuch
hand
hygien
wear
glove
mask
isol
symptomat
patientshav
emphas
recommend
healthcar
worker
famili
member
patient
vaccin
influenza
well
undergo
postexposur
prophylaxi
korea
influenza
guidelin
oseltamivir
administ
prophylact
day
immunocompromis
patient
come
contact
patient
confirm
influenza
influenzalik
ill
crvurti
progress
lrti
therapeut
agent
limit
import
identifi
crvurti
patient
increas
risk
lrti
treatment
rsvurti
aerosol
ribavirin
significantli
reduc
frequenc
progress
lrti
vs
addit
follow
immunodefici
score
index
propos
neutropenia
cellsmm
point
lymphopenia
cellsmm
point
age
year
point
myeloabl
condit
point
gvhd
acutechron
point
corticosteroid
point
preengraft
within
day
transplant
point
score
associ
significantli
increas
risk
progress
lrti
suggest
necess
criteria
identifi
highrisk
group
palivizumab
human
antirsv
monoclon
antibodi
reduc
progress
lrti
hsct
patient
current
recommend
prophylact
usag
highrisk
children
risk
factor
progress
lrti
discuss
piv
human
metapneumoviru
rhinoviru
urti
treatment
recommend
lack
evid
oseltamivir
zanamivir
peramivir
use
treat
influenza
urti
lrti
administ
within
hour
symptom
onset
delay
administr
also
benefici
agent
administ
even
hour
although
definit
evid
guidelin
recommend
antivir
treatment
extend
korean
journal
intern
medicin
vol
march
beyond
usual
durat
case
sever
influenza
lrti
aerosol
ribavirin
intraven
immunoglobulin
ivig
combin
treatment
significantli
reduc
rsvlrtirel
mortal
thu
recommend
guidelin
although
evid
lack
aerosol
ribavirin
use
oral
ribavirin
intraven
ribavirin
may
consid
recent
doubleblind
placebocontrol
studi
presatovir
oral
rsventri
inhibitor
involv
rsvinfect
healthi
adult
volunt
receiv
rsv
challeng
intranas
reduc
viral
load
sever
clinic
diseas
proven
pivlrti
treat
aerosol
ribavirin
ivig
combin
unfortun
aerosol
ribavirin
costli
avail
korea
orphan
essenti
drug
center
korea
use
limit
antivir
avail
treat
crv
rhinoviru
human
metapneumoviru
bocaviru
lrti
support
care
mainstay
hsct
patient
crv
infect
often
suscept
pathogen
workup
coexist
pathogen
requir
aureu
pneumonia
infect
commonli
follow
influenza
infect
therefor
patient
influenza
lrti
administ
antibiot
bacteria
suscept
possibl
distinguish
bacteria
copathogen
ie
pcp
cmv
fungi
etc
use
imag
test
clinic
symptom
examin
bronchoscopi
requir
tuberculosi
tb
import
opportunist
infect
among
hsct
recipi
incid
higher
gener
popul
howev
lower
solidorgantranspl
patient
hsct
recipi
immunosuppress
result
hematolog
diseas
chemotherapi
radiotherapi
immunosuppress
agent
gvhd
sever
risk
factor
develop
tb
hsct
report
includ
acut
myeloid
leukemia
chronic
myeloid
leukemia
myelodysplast
syndrom
busulfan
cyclophosphamid
tbi
corticosteroid
therapi
hlamismatch
transplant
gvhd
histori
tb
infect
hsct
patient
develop
tb
undergon
allogen
autolog
transplant
respect
singlecent
studi
perform
korea
report
allogen
hsct
recipi
diagnos
tb
hsct
median
time
develop
tb
day
transplant
rang
standard
incid
ratio
tb
compar
gener
popul
ci
extens
chronic
gvhd
associ
develop
tb
p
fig
anoth
center
korea
report
hsct
patient
tbibas
condit
like
tb
diseas
extrapulmonari
tb
compris
posthsct
tb
case
higher
gener
popul
owe
risk
reactiv
new
infect
prophylaxi
recommend
hsct
recipi
posit
tbspecif
releas
assay
result
isoniazid
well
toler
posthsct
period
howev
concurr
itraconazol
recommend
due
drug
interact
impact
voriconazol
posaconazol
unclear
isoniazid
contin
u
least
month
immunosuppress
reduc
rifampin
may
undergo
drugdrug
interact
immunosuppress
make
option
practic
determin
optimum
time
durat
isoniazid
prophylaxi
hsct
patient
studi
need
posthsct
vaccin
recommend
regardless
type
transplant
sourc
stem
cell
guidelin
recommend
allogen
autolog
hsct
recipi
immun
schedul
even
immunosuppress
therapi
chronic
gvhd
howev
mgkg
prednisolon
administ
gvhd
may
temporarili
delay
increas
immun
respons
dosag
immunosuppress
becom
decreas
recommend
schedul
korea
present
tabl
hsct
perform
treat
variou
hematolog
malign
disord
although
surviv
rate
improv
due
develop
transplant
techniqu
infecti
complic
remain
major
caus
morbid
mortal
hsct
sever
infecti
complic
vari
accord
phase
posttranspl
type
transplant
gvhd
degre
immunosuppress
reconstitut
studi
requir
improv
treatment
infecti
diseas
outcom
hsct
patient
expect
improv
futur
potenti
conflict
interest
relev
articl
report
hsct
hematopoiet
stem
cell
transplant
follow
three
dose
pneumococc
conjug
vaccin
pcv
dose
polysaccharid
pneumococc
vaccin
may
given
broaden
cover
spectrum
hsct
recipi
chronic
graftversushost
diseas
gvhd
like
respond
poorli
polysaccharid
vaccin
fourth
pcv
consid
interv
month
b
dtap
diphtheriatetanusreduc
acellular
pertussi
vaccin
prefer
tetanu
toxoidreduc
diphtheria
toxoidreduc
acellular
pertussi
vaccin
tdap
tdap
avail
use
c
reimmun
td
tetanu
toxoidreduc
diphtheria
toxoid
vaccin
tdap
least
everi
year
indic
month
hsct
gvhd
ongo
immunosuppress
patient
seroneg
vaccin
